MRCP+
General Information
Product name
Company
Subspeciality
Modality
Disease targeted
Main task
Not specified
Technical Specifications
Population
Not specified
Patient population age
Not specified
Input
Input format
Not specified
Output
Not specified
Output format
Not specified
Integration
Not specified
Deployment
Not specified
Trigger for analysis
Not specified
Processing time
Not specified
Regulatory Information
Pathway:
MDD
Class:
Class I
Pathway:
510(k) cleared
Class:
Class II
Other certifications
Not specified
Market Presence
On market since
AI Platforms
Resellers
Not specified
Countries present
Not specified
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
Not specified
Based on
Not specified
Evidence & Research
Peer-Reviewed Papers
View
Quantitative <scp>MRCP</scp> and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study
Other Articles
View
Pilot feasibility study to determine the utility of direct access and quantitative magnetic resonance cholangiopancreatography (MRCP) in the assessment of suspected acute biliary or ductal gallstone presentations
Source: public | First published: May 2, 2024 | Last updated: Jul 11, 2025